Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vintafolide - Endocyte

Drug Profile

Vintafolide - Endocyte

Alternative Names: EC-145; Folic acid desacetylvinblastine hydrazine conjugate; MK-8109; VYNFINIT

Latest Information Update: 06 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Endocyte
  • Class Amino acids; Antineoplastics; Folic acids; Hydrazines; Pterins; Sulfhydryl compounds; Vinca alkaloids
  • Mechanism of Action Microtubule protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Submission Withdrawal Ovarian cancer
  • No development reported Non-small cell lung cancer; Solid tumours
  • Discontinued Endometrial cancer

Most Recent Events

  • 06 Aug 2019 No development reported - Phase-II for Non-small cell lung cancer (Combination therapy, Monotherapy, Second-line therapy or greater) in Poland, Germany, France, Spain, Russia, Romania, Hungary, Czech Republic, United Kingdom, Bulgaria, USA (IV) (Endocyte website, August 2019)
  • 21 Dec 2018 Endocyte has been acquired by Novartis
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top